Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study for the Long Term Evaluation of Fostamatinib for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome (ARDS)
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Fostamatinib (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions
- Acronyms FOSTA-ARDS
Most Recent Events
- 14 Mar 2025 Planned End Date changed from 31 Oct 2025 to 31 Oct 2026.
- 14 Mar 2025 Planned primary completion date changed from 31 Aug 2025 to 31 May 2026.
- 14 Mar 2025 Planned initiation date changed from 1 Feb 2025 to 1 May 2025.